Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a **combination therapy** consisting of *autologous platelet-rich plasma gel* and *autologous platelet-rich plasma injection*. Both components are derived from a patient's own blood (autologous), processed to concentrate platelets and associated growth factors, and then either injected or applied as a gel to the target tissue. The mechanism centers on delivering high concentrations of platelets, growth factors, and bioactive molecules to injured or diseased tissues, stimulating healing and tissue regeneration via enhanced cell proliferation, angiogenesis, and extracellular matrix synthesis. The gel formulation is typically created by activating the PRP (often with thrombin or calcium chloride), resulting in a semisolid matrix that localizes growth factor release, commonly used for wound coverage. The injection form introduces concentrated PRP directly into tissues or joints to facilitate in situ repair. Indications include chronic wounds (such as diabetic foot ulcers, venous leg ulcers), musculoskeletal injuries, osteoarthritis, dermatological rejuvenation, and additional applications where enhanced tissue repair is sought[1][2][3][4][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on autologous platelet rich plasma gel + autologous platelet rich plasma injection.